Literature DB >> 10074517

Comparison of isolation media for recovery of Burkholderia cepacia complex from respiratory secretions of patients with cystic fibrosis.

D Henry1, M Campbell, C McGimpsey, A Clarke, L Louden, J L Burns, M H Roe, P Vandamme, D Speert.   

Abstract

Burkholderia cepacia selective agar (BCSA) has previously been devised for isolation of B. cepacia from respiratory secretions of patients with cystic fibrosis and tested under research laboratory conditions. Here we describe a study in which BCSA, oxidation-fermentation polymyxin bacitracin lactose agar (OFPBL), and Pseudomonas cepacia agar (PCA) were compared in routine culture procedures for the ability to grow B. cepacia and inhibit other organisms. Three hundred twenty-eight specimens from 209 patients at two pediatric centers and 328 specimens from 109 adults were tested. Plates were inoculated, incubated, and read for quality and quantity of growth at 24, 48, and 72 h. Five (1.5%) specimens from 4 (1.9%) children and 75 (22.9%) specimens from 16 (14.7%) adults grew B. cepacia complex. At 24, 48, and 72 h, BCSA achieved 43, 93, and 100% detection, respectively; OFPBL achieved 26, 84, and 96%, respectively; and PCA achieved 33, 74, and 84% detection, respectively. Quality was assessed as pinpoint or good growth. At 24 h, most cultures growing B. cepacia complex had pinpoint colonies. By 48 and 72 h, 48 and 69% of B. cepacia complex cultures, respectively, had good growth on BCSA, while on OFPBL 19 and 30%, respectively, had good growth and on PCA 11 and 18%, respectively, had good growth. BCSA was superior to OFPBL and PCA in suppressing organisms other than B. cepacia complex; 40 non-B. cepacia complex organisms were isolated from BCSA, 263 were isolated from OFPBL, and 116 were isolated from PCA. We conclude that BCSA is superior to OFPBL and PCA in its ability to support the growth of B. cepacia complex and to suppress other respiratory organisms.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10074517      PMCID: PMC88640     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  15 in total

1.  Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis.

Authors:  J R Govan; P H Brown; J Maddison; C J Doherty; J W Nelson; M Dodd; A P Greening; A K Webb
Journal:  Lancet       Date:  1993-07-03       Impact factor: 79.321

2.  Accuracy of four commercial systems for identification of Burkholderia cepacia and other gram-negative nonfermenting bacilli recovered from patients with cystic fibrosis.

Authors:  D L Kiska; A Kerr; M C Jones; J A Caracciolo; B Eskridge; M Jordan; S Miller; D Hughes; N King; P H Gilligan
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

3.  Isolation medium for the recovery of Pseudomonas cepacia from respiratory secretions of patients with cystic fibrosis.

Authors:  P H Gilligan; P A Gage; L M Bradshaw; D V Schidlow; B T DeCicco
Journal:  J Clin Microbiol       Date:  1985-07       Impact factor: 5.948

4.  Epidemic of Pseudomonas cepacia in an adult cystic fibrosis unit: evidence of person-to-person transmission.

Authors:  D L Smith; L B Gumery; E G Smith; D E Stableforth; M E Kaufmann; T L Pitt
Journal:  J Clin Microbiol       Date:  1993-11       Impact factor: 5.948

5.  Auxotrophy of Burkholderia (Pseudomonas) cepacia from cystic fibrosis patients.

Authors:  A L Barth; T L Pitt
Journal:  J Clin Microbiol       Date:  1995-08       Impact factor: 5.948

6.  Burkholderia (Pseudomonas) cepacia and cystic fibrosis: the epidemiology in Belgium.

Authors:  H Revets; P Vandamme; A Van Zeebroeck; K De Boeck; M J Struelens; J Verhaegen; J P Ursi; G Verschraegen; H Franckx; A Malfroot; I Dab; S Lauwers
Journal:  Acta Clin Belg       Date:  1996       Impact factor: 1.264

7.  Acquisition of Pseudomonas cepacia at summer camps for patients with cystic fibrosis. Summer Camp Study Group.

Authors:  D A Pegues; L A Carson; O C Tablan; S C FitzSimmons; S B Roman; J M Miller; W R Jarvis
Journal:  J Pediatr       Date:  1994-05       Impact factor: 4.406

8.  Xanthomonas maltophilia misidentified as Pseudomonas cepacia in cultures of sputum from patients with cystic fibrosis: a diagnostic pitfall with major clinical implications.

Authors:  D R Burdge; M A Noble; M E Campbell; V L Krell; D P Speert
Journal:  Clin Infect Dis       Date:  1995-02       Impact factor: 9.079

9.  Microbiology of sputum from patients at cystic fibrosis centers in the United States.

Authors:  J L Burns; J Emerson; J R Stapp; D L Yim; J Krzewinski; L Louden; B W Ramsey; C R Clausen
Journal:  Clin Infect Dis       Date:  1998-07       Impact factor: 9.079

10.  Inapparent transmission of Pseudomonas (Burkholderia) cepacia among patients with cystic fibrosis.

Authors:  J J Lipuma; K A Marks-Austin; D S Holsclaw; G B Winnie; P H Gilligan; T L Stull
Journal:  Pediatr Infect Dis J       Date:  1994-08       Impact factor: 2.129

View more
  23 in total

Review 1.  Infection control in cystic fibrosis: methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa and the Burkholderia cepacia complex.

Authors:  J R Govan
Journal:  J R Soc Med       Date:  2000       Impact factor: 5.344

2.  Comparative evaluation of the BD Phoenix and VITEK 2 automated instruments for identification of isolates of the Burkholderia cepacia complex.

Authors:  Sylvain Brisse; Stefania Stefani; Jan Verhoef; Alex Van Belkum; Peter Vandamme; Wil Goessens
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

Review 3.  Taxonomy and identification of the Burkholderia cepacia complex.

Authors:  T Coenye; P Vandamme; J R Govan; J J LiPuma
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

Review 4.  Laboratory aspects of management of chronic pulmonary infections in patients with cystic fibrosis.

Authors:  Melissa B Miller; Peter H Gilligan
Journal:  J Clin Microbiol       Date:  2003-09       Impact factor: 5.948

5.  Molecular typing of, and distribution of genetic markers among, Burkholderia cepacia complex isolates from Brazil.

Authors:  Maria G Detsika; John E Corkill; Marcelo Magalhães; Kerry J Glendinning; C Anthony Hart; Craig Winstanley
Journal:  J Clin Microbiol       Date:  2003-09       Impact factor: 5.948

6.  Quorum sensing inhibitors increase the susceptibility of bacterial biofilms to antibiotics in vitro and in vivo.

Authors:  Gilles Brackman; Paul Cos; Louis Maes; Hans J Nelis; Tom Coenye
Journal:  Antimicrob Agents Chemother       Date:  2011-03-21       Impact factor: 5.191

7.  Functional analysis of the Burkholderia cenocepacia ZmpA metalloprotease.

Authors:  C Kooi; C R Corbett; P A Sokol
Journal:  J Bacteriol       Date:  2005-07       Impact factor: 3.490

8.  Burkholderia cenocepacia ZmpB is a broad-specificity zinc metalloprotease involved in virulence.

Authors:  C Kooi; B Subsin; R Chen; B Pohorelic; P A Sokol
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

Review 9.  Burkholderia cepacia Complex Bacteria: a Feared Contamination Risk in Water-Based Pharmaceutical Products.

Authors:  Mariana Tavares; Mariya Kozak; Alexandra Balola; Isabel Sá-Correia
Journal:  Clin Microbiol Rev       Date:  2020-04-15       Impact factor: 26.132

10.  Microbiological and epidemiological features of clinical respiratory isolates of Burkholderia gladioli.

Authors:  Christine Segonds; Patricia Clavel-Batut; Michelle Thouverez; Dominique Grenet; Alain Le Coustumier; Patrick Plésiat; Gérard Chabanon
Journal:  J Clin Microbiol       Date:  2009-03-18       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.